[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Tumuluri K, Kourt G, Martin P: Mitomycin C in sebaceous gland carcinoma with pagetoid spread. Br J Ophthalmol; 2004 May;88(5):718-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C in sebaceous gland carcinoma with pagetoid spread.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Eyelid Neoplasms / drug therapy. Mitomycin / therapeutic use. Sebaceous Gland Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Oct;108(10):1877-83 [11581065.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121 [11713084.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1984 Feb;102(2):245-9 [6696670.001]
  • [Cites] Am J Ophthalmol. 1986 Jul 15;102(1):87-90 [3728630.001]
  • [Cites] Surv Ophthalmol. 1989 May-Jun;33(6):477-90 [2658172.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):113-22 [7076199.001]
  • (PMID = 15090432.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1772123
  •  go-up   go-down


2. Atique-Tacla M, Paves L, Pereira MD, Manso PG: [Exenteration: a retrospective study]. Arq Bras Oftalmol; 2006 Sep-Oct;69(5):679-82
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data regarding sex, age, race, primary lesion site, visual acuity at the moment of diagnosis, previous surgeries related to the exenteration, type of performed surgery, histopathologic diagnosis, postoperative complications and use of adjuvant treatment were collected.
  • All lesions that led to exenteration were malignant neoplasias; however, none were metastatic.
  • Cases were also classified as squamous cell carcinoma (eleven cases), basal cell carcinoma (four cases), sebaceous gland carcinoma (two cases), rhabdomyosarcoma (two cases), mucoepidermoid carcinoma (one case) and adnexal microcistic carcinoma (one case).
  • Visual acuity at the moment of diagnosis ranged from 20/40 to no light perception.
  • Six patients needed postoperative radiotherapy and two had been previously submitted to chemotherapy.
  • CONCLUSION: Most patients analyzed in our study presented lesions that are usually small in the beginning; however, they can disseminate to the orbit in the absence of adequate treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Eye Neoplasms / surgery. Orbit Evisceration. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child, Preschool. Conjunctival Neoplasms / diagnosis. Continental Population Groups. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Period. Retrospective Studies. Sex Distribution. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187134.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


Advertisement
4. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • BCC is mainly located on sun exposed sites, being head and neck the areas of more incidence; although nose, eyelids and periorbitary tissue are unfavorable due to cosmetic results that BCC involves.
  • Several treatment options as surgical and non-surgical are available.
  • The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable.
  • Mohs' micrographic surgery is the standard treatment for all non-melanoma skin cancer.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The tissue beneath the surgical site can be left for second-intention granulation or covered with a cutaneous implant of partial thickness.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


5. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL: Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg; 2005 Mar;21(2):92-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.
  • PURPOSE: To determine incidence and distribution of conjunctival epithelial involvement by eyelid sebaceous carcinoma and to make recommendations regarding its management.
  • METHODS: The medical records were reviewed retrospectively on patients with histopathologically confirmed sebaceous carcinoma of the eyelids managed at the Oncology Service at Wills Eye Hospital.
  • Based on these findings and personal surgical experience, recommendations are made regarding management of eyelid sebaceous carcinoma with involvement of the conjunctival epithelium.
  • RESULTS: Of 60 patients with sebaceous carcinoma, epithelial involvement of the conjunctiva was identified in 28 (47%).
  • Map biopsies, combined with cryotherapy, topical chemotherapy, local surgical resection, and orbital exenteration, were used to achieve local control.
  • CONCLUSIONS: Eyelid sebaceous carcinoma was found to exhibit epithelial involvement of the conjunctiva in 47% of cases, predominantly in the superior tarsal and fornical conjunctiva and less often in the inferior tarsal conjunctiva, caruncle, and cornea.
  • Treatment of this condition is challenging, and map biopsy, cryotherapy, topical chemotherapy, and newer surgical methods are being used more often by our group.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma in Situ / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryotherapy. Humans. Incidence. Ophthalmologic Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778660.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA: Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):307-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
  • A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil.
  • Eyelid-sparing orbital exenteration was performed after 3 cycles of chemotherapy, followed by radiotherapy to the regional lymph nodes.
  • Subsequently, 3 cycles of adjuvant chemotherapy were administered.
  • Significant eyelid and orbital tumor volume reduction was achieved with neoadjuvant chemotherapy, making eyelid-sparing orbital exenteration possible.
  • Chemotherapy also spared the patient from radical neck dissection.
  • The patient had limited morbidity and was free of local, regional, and systemic disease at 26 months of follow-up.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052148.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Russell HC, Chadha V, Lockington D, Kemp EG: Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol; 2010 Oct;94(10):1316-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
  • The aim of this study is to determine outcomes and complications following such treatment.
  • METHODS: This study is a retrospective review of patients treated with topical MMC for ocular surface neoplasia, including primary acquired melanosis (PAM), melanoma, corneal-conjunctival intraepithelial neoplasia (CCIN), squamous cell carcinoma (SCC) and sebaceous gland carcinoma (SGC).
  • Data regarding diagnosis, short- and long-term outcomes, and short- and long-term complications, were recorded.
  • RESULTS: 58 patients were identified, with a mean age of 63 years and mean follow-up of 36 months.
  • 21 received MMC as primary therapy and 37 as surgical adjuvant.
  • The regimen was 0.04% MMC four times a day for 3 weeks on, 3 weeks off, 3 weeks on, with topical steroid and lubricants throughout.
  • Overall, 26% developed recurrent disease at a mean of 13 months post treatment.
  • Short-term complications occurred in 52%, but only 7% required treatment cessation.
  • CONCLUSION: The results confirm the effectiveness of topical MMC chemotherapy in the management of ocular surface neoplasia.
  • Self-limiting short-term complications were common; however, limbal stem cell deficiency appears to be a significant long-term complication of treatment, occurring in 12%.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


8. Shields CL, Naseripour M, Shields JA, Eagle RC Jr: Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology; 2002 Nov;109(11):2129-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin-C for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • INTERVENTION: All patients received topical 0.04% mitomycin-C four times daily for 1 week followed by 1 week off medication.
  • The treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • PARTICIPANTS: Four patients with histopathologically proven intraepithelial (pagetoid) invasion of the conjunctiva by sebaceous gland carcinoma were managed with this regimen.
  • Before treatment, the main tumor site included the upper eyelid in two cases and the lower eyelid in two cases.
  • At the time of our examination, map biopsies confirmed pagetoid invasion involving 25% to 90% of the conjunctival surface, with bulbar, forniceal, and tarsal conjunctival involvement in all four cases and corneal extension in one case.
  • After treatment, medication intolerance and early discontinuation occurred in one patient, and continued tumor progression was documented.
  • Of the remaining three patients, chemotherapy was used for a mean of four cycles with complete resolution of the pagetoid invasion, confirmed histopathologically in two cases, and without recurrence in all three cases over 12 months (mean) follow-up.
  • The medication caused moderate temporary local irritation but no serious intraocular or extraocular complications.
  • CONCLUSIONS: Preliminary evidence suggests that topical mitomycin-C is effective treatment for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Eyelid Neoplasms / drug therapy. Mitomycin / therapeutic use. Sebaceous Gland Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12414427.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


9. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL: Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol; 2005 Mar-Apr;50(2):103-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous carcinoma of the ocular region: a review.
  • Sebaceous carcinoma of the ocular region is a malignant neoplasm that is being recognized more frequently and managed by innovative techniques of local resection, cryotherapy, topical chemotherapy, and radiotherapy, resulting in improved visual and systemic prognosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Eyelid Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cryotherapy. Eye Neoplasms / pathology. Eye Neoplasms / therapy. Humans. Mohs Surgery. Radiotherapy

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749305.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 168
  •  go-up   go-down


10. Oshiro H, Iwai T, Hirota M, Mitsudo K, Tohnai I, Minamimoto R, Omura-Minamisawa M, Nagashima Y, Yamanaka S, Fukui T, Kanazawa M, Sagawa H, Mita K, Nakayama T, Inayama Y: Primary sebaceous carcinoma of the tongue. Med Mol Morphol; 2010 Dec;43(4):246-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sebaceous carcinoma of the tongue.
  • Sebaceous carcinoma is the rarest type of oral malignancies.
  • We report a case of primary sebaceous carcinoma of the tongue.
  • Superselective intraarterial chemotherapy was administered via the superficial temporal artery concurrent with daily radiotherapy.
  • Our case demonstrates that superselective intraarterial chemotherapy combined with concurrent radiotherapy can be effective in treating the primary lesion of patients with a sebaceous carcinoma of the tongue.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1090-100 [18411003.001]
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):79-84 [15599352.001]
  • [Cites] J Laryngol Otol. 1996 May;110(5):500-2 [8762330.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 May;135(5):511-4 [19451474.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Apr;41(2):84-7 [12694699.001]
  • [Cites] J Cutan Pathol. 2008 Jul;35(7):641-6 [18201230.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):776-83 [10369589.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):158-65 [18988294.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jul;264(7):829-32 [17285332.001]
  • [Cites] Nagoya J Med Sci. 2006 Jun;68(3-4):101-8 [16967775.001]
  • [Cites] J Clin Pathol. 2006 Nov;59(11):1166-70 [16556662.001]
  • [Cites] J Cutan Pathol. 2008 Jan;35(1):40-5 [18095993.001]
  • [Cites] Br J Cancer. 2008 Mar 25;98(6):1039-45 [18283309.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Dec;72(6):709-11 [1812454.001]
  • [Cites] Eye (Lond). 1999;13 ( Pt 1):104-8 [10396393.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):634-41 [16965339.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jul;55(7):751-4 [9216510.001]
  • [Cites] Pathol Int. 2005 Mar;55(3):137-43 [15743322.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1953 Sep;6(9):1072-7 [13088005.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Aug;26(4):293-4 [9258724.001]
  • [Cites] Ophthalmologica. 2007;221(5):331-9 [17728556.001]
  • [Cites] Pathol Int. 2008 Aug;58(8):483-8 [18705767.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1428-35 [20605340.001]
  • (PMID = 21267703.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Duman DG, Ceyhan BB, Celikel T, Ahiskali R, Duman D: Extraorbital sebaceous carcinoma with rapidly developing visceral metastases. Dermatol Surg; 2003 Sep;29(9):987-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
  • BACKGROUND: Extraorbital sebaceous carcinoma (SC) is a rare carcinoma of the skin but is known to have a good prognosis in terms of metastasis and survival.
  • The patient did not benefit from the docetaxel chemotherapy regimen applied after the distant metastases were developed.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Glandular and Epithelial / pathology. Paclitaxel / analogs & derivatives. Sebaceous Gland Neoplasms / pathology. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Fatal Outcome. Female. Humans. Neoplasm Metastasis. Orbit. Viscera

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12930349.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S: Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg; 2010 Sep-Oct;26(5):366-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy.
  • A 35-year-old man presented with a recurrent temporal conjunctival mass (25 × 12 mm) involving about six-clock hours of the limbus in the left eye.
  • Histopathology showed it to be invasive sebaceous cell carcinoma.
  • At thirty-six weeks after treatment the left eye recorded a visual acuity of finger counting at 1 meter distance and no recurrence.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856079.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • RESULTS: The study included four women with a mean age of 66 years.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • Treatment of regional nodal metastasis consisted of complete neck dissection followed by radiation therapy.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • Systemic chemotherapy was considered for two additional patients: in one, chemotherapy was deferred due to poor performance status and ongoing medical problems; and another patient died before chemotherapy could be started.
  • The patient with bony metastasis was treated with radiation therapy to the spine.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • CONCLUSION: Eyelid sebaceous cell carcinoma can result in systemic metastasis and death.
  • Metastasis can be discovered as late as 5 years after treatment of the eyelid carcinoma, warranting continued surveillance.
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rosner M, Hadar I, Rosen N: Successful treatment with mitomycin C eye drops for conjunctival diffuse intraepithelial neoplasia with sebaceous features. Ophthal Plast Reconstr Surg; 2003 Nov;19(6):477-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with mitomycin C eye drops for conjunctival diffuse intraepithelial neoplasia with sebaceous features.
  • Conjunctival biopsy specimens from the right eye of a 66-year-old woman who had a 10-year history of an irritated and swollen right upper eyelid were diagnosed as diffuse intraepithelial neoplasia with sebaceous features.
  • The treatment consisted of two courses, 2 weeks apart, of 0.02% mitomycin C eye drops.
  • Severe trichiasis that developed after the biopsies was managed surgically.
  • Today, 46 months after completion of mitomycin C treatment, the conjunctiva shows no inflammation, the eyelid is not swollen or irritated, and there is no clinical indication of recurrence.
  • This case report demonstrates that conjunctival diffuse intraepithelial neoplasia of the conjunctiva with sebaceous features can be successfully treated by treatment with mitomycin C drops.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / pathology. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14625495.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


15. Myers M, Gurwood AS: Periocular malignancies and primary eye care. Optometry; 2001 Nov;72(11):705-12
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We surveyed the literature regarding the incidence, diagnosis, differential diagnosis, management, prognosis, and prevention of the most common periocular malignancies.
  • The types of malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma.
  • Up to 20% of periocular skin lesions are malignant.
  • Workup for these entities includes biopsy as the first step in diagnosis and management of skin cancers.
  • Treatment alternatives, used when surgical intervention is unable to be tolerated, include radiation therapy, cryotherapy, chemotherapy, interferons, and recently developed photodynamic therapy.
  • CONCLUSION: The importance of gross observation, examination, and careful slit-lamp biomicroscopy of the ocular adnexa cannot be overstated as a means of detection, diagnosis, and management of beginning, impending, or worsening malignancies.
  • [MeSH-major] Eye Neoplasms / diagnosis. Primary Health Care / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Prognosis. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12363258.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


16. Babilas P, Schreml S, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed; 2010 Jun;26(3):118-32
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in dermatology: state-of-the-art.
  • Photodynamic therapy (PDT) has become an established treatment modality for dermatooncologic conditions like actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and superficial basal cell carcinoma.
  • Aesthetic indications like photo-aged skin or sebaceous gland hyperplasia complete the range of applications.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584250.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


17. Babilas P, Szeimies RM: The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol; 2010 Oct;145(5):613-30
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of photodynamic therapy in dermatology.
  • In dermatology, topical photodynamic therapy (PDT) is a well established treatment modality which has mainly shown to be effective for dermato-oncologic conditions like actinic keratosis, Bowen's disease, in-situ squamous cell carcinoma and superficial basal cell carcinoma.
  • However, a therapeutical benefit of PDT is also evident for inflammatory dermatoses like localized scleroderma, acne vulgaris and granuloma annulare as well as for aesthetic indications like photo aged skin or sebaceous gland hyperplasia.
  • These drugs do not induce strong generalized cutaneous photosensitization like the systemically applied porphyrins or their derivatives.
  • Treating superficial oncologic lesions (tumor thickness < 2-3 mm) cure rates achieved by PDT are equal to the cure rates of the respective standard therapeutic procedure.
  • The benefits of PDT are the low level of invasiveness and the excellent cosmetic results after treatment.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Carcinoma, Basal Cell / drug therapy. Cosmetic Techniques. Humans. Keratosis, Actinic / drug therapy. Light. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Neoplasms / drug therapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930696.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


18. Poothullil AM, Colby KA: Topical medical therapies for ocular surface tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):161-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical medical therapies for ocular surface tumors.
  • We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B.
  • Topical agents were used as both primary and adjuvant therapy.
  • Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymphoma / drug therapy. Lymphoma / pathology. Mitomycin / administration & dosage. Mitomycin / adverse effects. Recombinant Proteins. Sebaceous Gland Neoplasms / drug therapy. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912014.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


19. Graefe T, Wollina U, Schulz H, Burgdorf W: Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology; 2000;200(4):331-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development.
  • Muir-Torre syndrome is a genodermatosis in which multiple internal malignancies are associated with cutaneous sebaceous tumours and kerato-acanthomas.
  • A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma.
  • 3 x 10(6) U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel.
  • During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Humans. Interferon-alpha / administration & dosage. Isotretinoin / administration & dosage. Male. Middle Aged. Recombinant Proteins. Skin / drug effects. Skin / pathology. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10894967.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 47RRR83SK7 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


20. Holbach LM, Pogorelov P, Kruse FE: [Differential diagnosis and treatment options for conjunctival tumors]. Ophthalmologe; 2007 Jun;104(6):521-38; quiz 538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment options for conjunctival tumors].
  • Further imaging procedures are rarely indicated when malignant processes are not circumscribed.
  • Essential in practice is the histopathological confirmation of the clinical diagnosis, e.g., distinguishing between nonpigmented melanomas and sebaceous gland carcinomas with a pagetoid growth pattern or squamous cell carcinomas.
  • Depending on the course and findings, the following therapeutic measures can be indicated: cryotherapy, chemotherapy, radiotherapy, modified enucleation, orbital exenteration, or a combination of different methods.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Conjunctiva / pathology. Diagnosis, Differential. Humans. Lymphatic Metastasis / pathology. Melanoma / diagnosis. Melanoma / pathology. Melanoma / therapy. Neoplasm Staging. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Nevus, Pigmented / therapy. Ophthalmoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologe. 2002 Jun;99(6):490-507; quiz 508-9 [12125420.001]
  • [Cites] Orbit. 2000 Mar;19(1):13-19 [12045960.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):674-8 [15224213.001]
  • [Cites] Klin Monbl Augenheilkd. 1999 Oct;215(4):263-5 [10572892.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):163-7 [11815341.001]
  • [Cites] Klin Monbl Augenheilkd. 1995 Oct;207(4):239-46 [8587298.001]
  • [Cites] Klin Monbl Augenheilkd. 1987 Feb;190(2):105-8 [3553717.001]
  • [Cites] Klin Monbl Augenheilkd. 2001 Apr;218(4):269-72 [11392273.001]
  • [Cites] Klin Monbl Augenheilkd. 2002 Jun;219(6):462-4 [12136445.001]
  • [Cites] Curr Opin Ophthalmol. 1995 Aug;6(4):39-43 [10150881.001]
  • [Cites] Br J Ophthalmol. 2001 Jun;85(6):658-61 [11371482.001]
  • [Cites] Klin Monbl Augenheilkd. 1994 Oct;205(4):242-3 [7823524.001]
  • [Cites] Arch Ophthalmol. 2000 Oct;118(10):1437-40 [11030832.001]
  • [Cites] Hum Mutat. 2006 Feb;27(2):155-62 [16395674.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Klin Monbl Augenheilkd. 1986 Aug;189(2):128-32 [3531699.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Ophthalmologe. 2002 May;99(5):394-411; quiz 412-3 [12043298.001]
  • [Cites] Ophthalmologe. 2003 Sep;100(9):708-12 [14504895.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Am J Ophthalmol. 2002 Jul;134(1):147-8 [12095833.001]
  • [Cites] Eur J Ophthalmol. 1992 Jan-Mar;2(1):3-9 [1322210.001]
  • [Cites] Ophthalmologe. 2006 Feb;103(2):124-8 [16047150.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Klin Monbl Augenheilkd. 1985 Sep;187(3):212-4 [2415746.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1776-9 [14662600.001]
  • [Cites] J Fr Ophtalmol. 1995;18(6-7):481-3 [7560791.001]
  • [Cites] Br J Ophthalmol. 1997 Feb;81(2):168 [9059254.001]
  • (PMID = 17530261.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement